<DOC>
	<DOCNO>NCT00500955</DOCNO>
	<brief_summary>Following 4-week single-blind placebo run-in period , eligible subject randomize 1:1 ratio receive 32 week double-blind study medication : Rosiglitazone ( start dose 4mg od ) Glyburide ( start dose 5mg od ) , combination open-label Metformin &gt; = ( 1g/day ) . Subjects stratify use ACEI , nondihydropyridine calcium channel blocker ( NDP CCB ) , angiotensin II receptor blocker ( ARB ) provide equal representation subject treatment group .</brief_summary>
	<brief_title>Rosiglitazone Microalbuminuria Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Male female subject , age 4080 T2DM Microalbuminuria previously treat diet exercise alone , single oral antidiabetic agent , combination oral antidiabetic therapy . Pregnancy lactation , use TZD ( pioglitazone Rosiglitazone ) insulin , renal disease renal dysfunction , degree congestive heart failure , clinically significant hepatic disease anemia , presence unstable severe angina coronary insufficiency , high blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>microalbuminuria ,</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>rosiglitazone ,</keyword>
</DOC>